CHEMICAL AND PHYSICAL PROPERTIES
| Color/Form | White to off-white powder |
|---|---|
| Isoelectric Point | 4.86 |
| Other Experimental Properties | 39-amino acid synthetic peptide amide |
COMPUTED DESCRIPTORS
| Molecular Weight | 4187 g/mol |
|---|---|
| XLogP3 | -21 |
| Hydrogen Bond Donor Count | 58 |
| Hydrogen Bond Acceptor Count | 66 |
| Rotatable Bond Count | 135 |
| Exact Mass | 4185.0306624 g/mol |
| Monoisotopic Mass | 4184.0273075 g/mol |
| Topological Polar Surface Area | 1780 Ų |
| Heavy Atom Count | 295 |
| Formal Charge | 0 |
| Complexity | 10300 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 37 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.